Cantor Fitzgerald Predicts Pharvaris FY2026 Earnings

Pharvaris (NASDAQ:PHVS - Free Report) - Investment analysts at Cantor Fitzgerald issued their FY2026 earnings per share (EPS) estimates for shares of Pharvaris in a note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst S. Seedhouse expects that the company will earn ($3.75) per share for the year. Cantor Fitzgerald has a "Overweight" rating and a $25.00 price target on the stock. The consensus estimate for Pharvaris' current full-year earnings is ($2.71) per share.

Pharvaris (NASDAQ:PHVS - Get Free Report) last issued its quarterly earnings data on Tuesday, May 13th. The company reported ($0.89) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.80) by ($0.09).

Other equities research analysts also recently issued reports about the stock. Guggenheim assumed coverage on shares of Pharvaris in a report on Wednesday. They issued a "buy" rating and a $32.00 price target for the company. Wedbush reaffirmed an "outperform" rating and issued a $27.00 price target on shares of Pharvaris in a research note on Thursday, June 5th. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, Pharvaris presently has a consensus rating of "Buy" and an average target price of $36.20.

Pharvaris Stock Down 3.1%

NASDAQ PHVS traded down $0.53 on Wednesday, reaching $16.70. 12,409 shares of the stock traded hands, compared to its average volume of 74,118. Pharvaris has a 12 month low of $11.51 and a 12 month high of $25.50. The company has a market cap of $873.24 million, a price-to-earnings ratio of -5.96 and a beta of -2.86. The firm's fifty day simple moving average is $15.93 and its 200 day simple moving average is $16.87.

Hedge Funds Weigh In On Pharvaris

Several hedge funds have recently bought and sold shares of the business. Deutsche Bank AG increased its position in Pharvaris by 55.1% during the first quarter. Deutsche Bank AG now owns 28,174 shares of the company's stock worth $442,000 after buying an additional 10,006 shares during the last quarter. TD Asset Management Inc increased its position in Pharvaris by 41.5% during the first quarter. TD Asset Management Inc now owns 78,122 shares of the company's stock worth $1,227,000 after buying an additional 22,906 shares during the last quarter. Palumbo Wealth Management LLC increased its position in Pharvaris by 38.0% during the first quarter. Palumbo Wealth Management LLC now owns 14,102 shares of the company's stock worth $221,000 after buying an additional 3,881 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in Pharvaris by 30.3% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 63,734 shares of the company's stock worth $1,222,000 after buying an additional 14,838 shares during the last quarter. Finally, Woodline Partners LP acquired a new position in Pharvaris during the fourth quarter worth $853,000.

Pharvaris Company Profile

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.